{"title":"COMPLICACIONES DE LA DIABETES","authors":"","doi":"10.1016/S2530-0164(24)00108-3","DOIUrl":"https://doi.org/10.1016/S2530-0164(24)00108-3","url":null,"abstract":"","PeriodicalId":37725,"journal":{"name":"Endocrinologia, Diabetes y Nutricion","volume":"71 ","pages":"Pages S75-S93"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141239029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"SESIÓN ORAL 1: COMPLICACIONES DE LA DIABETES","authors":"","doi":"10.1016/S2530-0164(24)00090-9","DOIUrl":"https://doi.org/10.1016/S2530-0164(24)00090-9","url":null,"abstract":"","PeriodicalId":37725,"journal":{"name":"Endocrinologia, Diabetes y Nutricion","volume":"71 ","pages":"Pages S1-S4"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141239659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"TRATAMIENTO DE LA DIABETES TIPO 1","authors":"","doi":"10.1016/S2530-0164(24)00105-8","DOIUrl":"https://doi.org/10.1016/S2530-0164(24)00105-8","url":null,"abstract":"","PeriodicalId":37725,"journal":{"name":"Endocrinologia, Diabetes y Nutricion","volume":"71 ","pages":"Pages S62-S65"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141241894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Antonio Moreno Tirado , Pilar Rodríguez Ortega , José María Calle Isorna
{"title":"Hemoglobina J-Chicago: a propósito de una glicada discordante","authors":"Antonio Moreno Tirado , Pilar Rodríguez Ortega , José María Calle Isorna","doi":"10.1016/j.endinu.2024.01.012","DOIUrl":"10.1016/j.endinu.2024.01.012","url":null,"abstract":"","PeriodicalId":37725,"journal":{"name":"Endocrinologia, Diabetes y Nutricion","volume":"71 4","pages":"Pages 189-190"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140278018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Nuevas formulaciones de levotiroxina en el tratamiento del hipotiroidismo","authors":"Pedro Iglesias","doi":"10.1016/j.endinu.2023.11.001","DOIUrl":"https://doi.org/10.1016/j.endinu.2023.11.001","url":null,"abstract":"","PeriodicalId":37725,"journal":{"name":"Endocrinologia, Diabetes y Nutricion","volume":"71 3","pages":"Pages 93-95"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140096216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rosa Márquez-Pardo , María-Gloria Baena-Nieto , Juan-Antonio Córdoba-Doña , Concepción Cruzado-Begines , Lourdes García-García-Doncel , Manuel Aguilar-Diosdado , Isabel-María Torres-Barea
{"title":"Variabilidad glucémica al diagnóstico de diabetes gestacional como predictor de tratamiento farmacológico","authors":"Rosa Márquez-Pardo , María-Gloria Baena-Nieto , Juan-Antonio Córdoba-Doña , Concepción Cruzado-Begines , Lourdes García-García-Doncel , Manuel Aguilar-Diosdado , Isabel-María Torres-Barea","doi":"10.1016/j.endinu.2023.12.007","DOIUrl":"10.1016/j.endinu.2023.12.007","url":null,"abstract":"<div><h3>Introduction</h3><p>To establish whether glycemic variability (GV) parameters used when gestational diabetes mellitus (GDM) has been diagnosed could help predict the probability that a patient will need pharmacological treatment, and to analyze the link of these parameters to the development of maternal-fetal complications.</p></div><div><h3>Materials and methods</h3><p>A prospective study of 87 women with GDM who underwent retrospective continuous glucose monitoring (CGM) for 6<!--> <!-->days between weeks 26 and 32 of gestation, following diagnosis. The mean glycemia levels and GV variables were analyzed together with their link to maternal-fetal complications, and the need for pharmacological treatment. ROC (receiver operating characteristic) curves were developed to determine validity to detect the need for pharmacological treatment.</p></div><div><h3>Results</h3><p>Patients with higher mean glycemia (<em>P</em> <!--><<!--> <!-->0.001) and continuous overlapping of net glycemic action in a period of n-hours (CONGAn) (<em>P</em> <!-->=<!--> <!-->0.001) required pharmacological treatment. The ROC curves showed cut-off points of 98.81<!--> <!-->mg/dl for mean glycemia, and 86.70<!--> <!-->mg/dl for CONGAn, with 83.3% sensitivity and 67.8% specificity for both parameters. No relation between the GV parameters and development of maternal-fetal complications was observed.</p></div><div><h3>Conclusions</h3><p>The use of CGM, once GDM is diagnosed, enables us to identify those patients who would benefit from closer monitoring during gestation, and facilitate a speedier take-up of pharmacological treatment. However, prospective studies involving a higher number of patients are needed, as well as a cost assessment for recommending the use of CGM following GDM diagnosis.</p></div>","PeriodicalId":37725,"journal":{"name":"Endocrinologia, Diabetes y Nutricion","volume":"71 3","pages":"Pages 96-102"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139887250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ana Piñar-Gutiérrez , Suset Dueñas Disotuar , Irene de Lara-Rodríguez , Sandra Amuedo-Domínguez , Carmen González-Cejudo , José Tejero-Delgado , Miguel Ángel Mangas-Cruz
{"title":"Difficulties of gender affirming treatment in trans women with BRCA1+ mutation: A case report","authors":"Ana Piñar-Gutiérrez , Suset Dueñas Disotuar , Irene de Lara-Rodríguez , Sandra Amuedo-Domínguez , Carmen González-Cejudo , José Tejero-Delgado , Miguel Ángel Mangas-Cruz","doi":"10.1016/j.endinu.2023.12.006","DOIUrl":"10.1016/j.endinu.2023.12.006","url":null,"abstract":"<div><p>Gender affirming treatment in transgender women is based on a combination of antiandrogens and estrogens, with the latter maintained over the long term. When prescribing these treatments, we must consider the possibility of developing estrogen-dependent breast cancer. In transgender women, a breast cancer incidence of 4.1 per 100,000 has been estimated, which would increase the risk by 46% in relation to cisgender men but decrease it by 70% in relation to cisgender women. It is known that certain gene mutations such as BRCA1<span> imply an increased risk of breast cancer, but at present the risk in transgender women with BRCA1 treated with estrogens is not well established. We present the case of a transgender woman with a family history of breast cancer and BRCA1 mutation and the therapeutic decisions made in a multidisciplinary team. Following this case, we review and discuss the published literature.</span></p></div>","PeriodicalId":37725,"journal":{"name":"Endocrinologia, Diabetes y Nutricion","volume":"71 3","pages":"Pages 144-148"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139638305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
